Skip to main content

Table 1 Effect of TLR agonists on gene regulation in the tumor microenvironment

From: Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors

  Mean fold-change in mRNA levels (vs PBS treated controls)
Gene CpG ODN + 3M control 3M-052 + CpG control CpG ODN + 3M-052
IL-12 2.23* ± 0.18 1.40 ± 0.19 3.39*** ± 0.11
INFγ 1.94* ± 0.15 1.87* ± 0.25 2.81** ± 0.24
Granzyme B 1.69* ± 0.07 1.87* ± 0.08 4.44*** ± 0.23
Arg1 1.01 ± 0.09 0.63* ± 0.09 0.43** ± 0.08
Nos2 1.83 ± 0.05 0.39** ± 0.04 0.09** ± 0.04
CTLA-4 0.85* ± 0.03 0.52** ± 0.01 0.33*** ± 0.02
TGFβ 0.43* ± 0.03 0.45* ± 0.01 0.26** ± 0.02
  1. Mice were treated as described in Figure 1. mRNA was isolated from tumor infiltrating cells one day after the second treatment and analyzed by RT-PCR. Each point represents the mean ± SD fold difference in cells from treated vs untreated tumor bearing mice derived from independently studying 6 mice/group in 2 independent experiments.
  2. *, p < 0.05; **, p <0.01, ***, p <0.001 when compared to PBS treated controls. Note: the level of expression of all genes from mice treated with CpG ODN plus 3M-052 was also significantly different (p < .01 - 0.05) from that of mice treated with CpG ODN alone or 3M-052 alone.